Viessmann Generations Group has acquired a minority stake in PharOS, enhancing Europe's pharmaceutical supply chain amidst rising drug shortages.

Target Company Overview

The Viessmann Generations Group has acquired a significant minority stake in PharOS, a European pharmaceutical developer and manufacturer, as part of a consortium with Armira. PharOS, headquartered in Metamorfosi, Greece, specializes in the development, manufacturing, and supply of generics, over-the-counter (OTC) products, and value-added medications. The company emphasizes the production of complex generics aimed at critical treatment areas including oncology, central nervous system disorders, and cardiometabolic diseases. With an extensive global portfolio of over 100 products and over 9,200 marketing authorizations, PharOS successfully serves leading pharmaceutical companies while leveraging a robust European manufacturing presence and dependable supply chain.

Industry Overview in Europe

The pharmaceutical industry in Europe currently faces challenges related to drug shortages, driven by excessive dependency on products manufactured in Asia. These supply chains are exacerbated by geopolitical tensions and regulatory complexities, making local production increasingly vital. This heightened demand for local manufacturing capabilities is seen as a strategic necessity for maintaining the healthcare standards in European markets.

The generics market, particularly in the UK and the EU, has been generating significant revenue, with a strong push towards affordable medicines becoming paramount. The increase in chronic illnesses